Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in resistant BRAF V600-mutated advanced melanoma
NL-OMON47107Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vorinostat in melanoma and cutaneous malignancy, sponsored by Netherlands Cancer Institute. Primary endpoint: Antitumor activity / response rate. Started Jul 2016; status: active, not recruiting.
02
Drugs
vorinostat
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON47107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47107.